Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI plus DARZALEX FASPRO for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as ...

Approval based on unprecedented Phase 3 data demonstrating statistically significant improvements in progression-free survival and overall survival versus standard of care regimens83.3% of ...

Can Women Actually Be ‘Allergic’ to Their Boyfriends?

Beyond symptoms like burning, swelling, itching, and general irritation, it can even interfere with your ability to conceive.

New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech’s Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that a detailed analysis of the Phase III ALLEGORY trial of Gazyva® (obinutuzumab) in adults with systemic lupus ...
WJFW

argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline

Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients ...